APAC Ataxia Market - Industry Trends and Forecast to 2029

Segmentation

Short Description
Asia-Pacific Ataxia Market, By Type (Spinocerebellar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), Product (Treatment and Diagnosis), Dosage Form (Solid, Liquids, and Others), Route of Administration (Oral, Parenteral, and Others), Patient Type (Adult, Child, and Geriatric), End User (Hospital, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (China, India, Japan, Australia, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, and Rest of  Asia-Pacific) Industry Trends and Forecast to 2029

Market Definition:
Ataxia is a term for a group of disorders that affect co-ordination, balance, and speech. Any part of the body can be affected, but people with ataxia often have difficulties with balance and walking, speaking, swallowing tasks that require a high degree of control, such as writing and, eating, and vision. The exact symptoms and their severity vary depending on the type of ataxia a person has.
Ataxia usually results from damage to a part of the brain called the cerebellum, but it can also be caused by damage to other parts of the nervous system. This damage can be part of an underlying condition such as MS (multiple sclerosis) or can be caused by a head injury, lack of oxygen to the brain, or long-term, excessive alcohol consumption. Hereditary ataxia is caused by a faulty gene passed on by family members who may or may not be affected. 

Market Segmentation:
The Asia-Pacific ataxia market is categorized into seven notable segments based on type, product, dosage form, route of administration, patient type, end user, distribution channel.

 On the basis of type, the Asia-Pacific ataxia market is segmented into spinocerebellar ataxias, ataxia-telangiectasia, episodic ataxia, and others (multiple system atrophy (MSA))
 On the basis of product, the Asia-Pacific ataxia market is segmented into treatment and diagnosis
 On the basis of dosage form, the Asia-Pacific ataxia market is segmented into solid, liquids, and others
 On the basis of route of administration, the Asia-Pacific ataxia market is segmented into oral, parenteral, and others
 On the basis of patient type, the Asia-Pacific ataxia market is segmented into adult, child, and geriatric
 On the basis of end user, the Asia-Pacific ataxia market is segmented into hospital, clinics, home healthcare, and others
 On the basis of distribution channel, the Asia-Pacific ataxia market is segmented into direct tender, retail sales, and others

Market Players

Some of the key market players in the Asia-Pacific ataxia market are listed below:
 Novartis AG
 Merck KGaA
 Aurobindo Pharma.
 Pfizer Inc.
 Sanofi
 Teva Pharmaceutical Industries Ltd.
 Viatris Inc.
 Sun Pharmaceutical Industries Ltd.
 Lupin.
 Amneal Pharmaceuticals LLC.
 Apotex Inc.
 Cipla Inc.
 Reata Pharmaceuticals, Inc.
 Biohaven Pharmaceuticals

Methodology